ClinicalTrials.gg
RecruitingNCT07612774CAPRA-EVOUpdated Oct 7, 2026

CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS

A Phase 4 interventional study of Evolocumab and Serial photon-counting coronary computed tomography angiography in Coronary and Coronary Artery Disease, sponsored by West China Hospital. Recruiting at 2 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by West China Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2025, registered May 2026).
  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 7, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.

Planned enrollment
186th of 324
232 · median 307
Started
2025
with 40 others
Phase 4
66 of 543
14 open now
Primary completion
2028-10
later than 157 of 209 live
Registered
507th of 543
by date

Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 186th largest by planned enrollment of the 324 interventional ones that give a count, is one of 41 that started in 2025, is one of 66 in phase 4, reaches primary completion later than 157 of the 209 other live ones, and was the 507th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:

171 more — sign in →

All 176 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 543 studies in Coronary Artery Disease with a site in China, or all of them as a file.
02

Study summary

The CAPRA-EVO trial is a single-center, randomized, open-label study with blinded endpoint assessment comparing early evolocumab plus standard lipid-lowering therapy versus standard-of-care lipid-lowering therapy in patients with acute coronary syndrome after successful percutaneous coronary intervention. The study will use serial photon-counting coronary computed tomography angiography at baseline and 52 weeks to assess changes in non-culprit coronary plaque burden and stenosis severity. Secondary outcomes include changes in high-risk plaque features, lipid and inflammatory biomarkers, cardiovascular events, and safety outcomes. The trial aims to determine whether early intensive LDL-C lowering with evolocumab can reduce coronary plaque progression and support PCCT-CCTA as a noninvasive tool for monitoring atherosclerotic plaque dynamics.

03

Conditions studied

  • Coronary
  • Coronary Artery Disease

Keywords

  • acute coronary syndrome
  • coronary computed tomography angiography
  • proprotein convertase subtilisin/kexin type 9
  • randomized controlled trial
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligible patients must meet the following criteria:

  • Age between 40 and 75 years.
  • Diagnosis of ACS, including ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) or unstable angina (UA).
  • Successful PCI treatment, with post-procedural TIMI grade 3 flow and residual stenosis \<30% and atherosclerotic plaque presence in non-culprit coronary vessels (not attributed to this target event).
  • Suboptimal LDL-C control: Patients must have received any statin treatment for at least 4 weeks, with an LDL-C level ≥1.8 mmol/L; or Statin-naive patients must have an LDL-C level ≥3.2 mmol/L.
  • Agreement to complete baseline CCTA and laboratory tests within 7 days of enrollment and signed .
  • Commitment to complete 52 weeks of follow-up.

Exclusion criteria

Exclusion Criteria:

  • History of coronary artery bypass grafting (CABG).
  • History of valve surgery.
  • History of PCI treatment before the index ACS event
  • Complex bifurcation lesions (Medina 1,1,1).
  • Use of PCSK9 inhibitors (e.g., evolocumab, alirocumab) or potent inhibitors (e.g., itraconazole) within the last 12 months.
  • Known intolerance to statins, evolocumab, or other drugs related to the study.
  • Hepatic or renal insufficiency ( \<60 mL/min/1.73m² or /AST >3 times the ).
  • Active diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).
  • Uncontrolled heart failure ( class III-IV) or malignant arrhythmias.
  • Known allergy or to iodinated contrast media
  • Hyperthyroidism or active thyroid disease
  • Pregnancy or breastfeeding (or plans for pregnancy within the next year).
  • of less than 1 year (e.g., due to advanced ).
  • Participation in another interventional clinical trial within the past 3 months.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
232 participants (estimated)

Study arms

  • Experimental
    Experimental: Evolocumab Plus Standard Lipid-Lowering Therapy

    Participants randomized to this arm will receive early evolocumab in addition to standard-of-care lipid-lowering therapy after successful percutaneous coronary intervention for acute coronary syndrome. Participants will undergo serial photon-counting coronary computed tomography angiography at baseline and 52 weeks to evaluate changes in non-culprit coronary plaque burden, stenosis severity, and high-risk plaque features.

    Drug: Evolocumab · Diagnostic Test: Serial photon-counting coronary computed tomography angiography

  • Active comparator
    Active Comparator: Standard Lipid-Lowering Therapy

    Participants randomized to this arm will receive guideline-directed standard-of-care lipid-lowering therapy after successful percutaneous coronary intervention for acute coronary syndrome. Participants will undergo serial photon-counting coronary computed tomography angiography at baseline and 52 weeks to evaluate changes in non-culprit coronary plaque burden, stenosis severity, and high-risk plaque features.

    Diagnostic Test: Serial photon-counting coronary computed tomography angiography · Drug: Standard Lipid-Lowering Therapy

Interventions

  • Evolocumab will be administered early after randomization in participants assigned to the experimental arm, in addition to standard-of-care lipid-lowering therapy. The treatment is intended to achieve intensive low-density lipoprotein cholesterol reduction and to evaluate its effect on coronary plaque progression or stabilization over 52 weeks.

  • Diagnostic testSerial photon-counting coronary computed tomography angiography

    All participants will undergo photon-counting coronary computed tomography angiography at baseline and at 52 weeks. Imaging will be used to assess changes in total atherosclerotic volume, stenosis severity, and high-risk plaque features in non-culprit coronary vessels.

  • DrugStandard Lipid-Lowering Therapy

    Participants will receive guideline-directed standard lipid-lowering therapy according to contemporary clinical practice and investigator judgment.

06

What researchers measure

Primary outcomes

  1. Total atherosclerotic volume and stenosis severity

    a. Total atherosclerotic volume (TAV) at the whole-non-culprit-vessel level: Change from baseline CTA (week 0) to endpoint CTA(week 52).

    Time frame: From enrollment to the end of treatment at 52 weeks

  2. b. Stenosis severity at the target lesion level (defined as luminal stenosis ≥50%, particularly in left main coronary artery [LMCA] or proximal left anterior descending artery [LAD] OR presence of ≥2 high-risk plaque features)

    Time frame: From enrollment to the end of treatment at 52 weeks

Secondary outcomes

  1. HRP change

    Change in high-risk plaque (HRP) features from baseline CTA (week 0) to endpoint CTA (week 52).

    Time frame: From enrollment to the end of treatment at 52 weeks

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD that will be shared include anonymized data on baseline characteristics, primary and secondary outcome measures.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2028, 35 months after the start.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 35 months is close to that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start May 2026 → Nov 2025, primary completion Dec 2028 → Oct 2028 and completion Jan 2029 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 29, 2026
StartActual
Nov 19, 2025was May 2026
Primary completionEst.
Oct 31, 2028was Dec 2028
CompletionEst.
Dec 31, 2029was Jan 2029
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Tangdu Hospital, Air Force Medical University · Xi’an, China
Oct 7, 2026
Start date
May 19, 2026→Nov 19, 2025 (actual)
Oct 7, 2026
Primary completion
Dec 31, 2028→Oct 31, 2028
Oct 7, 2026
Study completion
Jan 31, 2029→Dec 31, 2029
Oct 7, 2026
Enrollment
233→232
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    1 site added
    Show site
    • Tangdu Hospital, Air Force Medical University · Xi’an, China
    Start date May 19, 2026→Nov 19, 2025 (now actual)
    Primary completion Dec 31, 2028→Oct 31, 2028
    Study completion Jan 31, 2029→Dec 31, 2029
    Enrollment 233→232
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07612774
Responsible party
Yong He (Professor, West China Hospital) — Principal investigator
First posted
May 29, 2026
Start date
Nov 19, 2025
Primary completion
Oct 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

Xiaoyu Wang
Contact
wxy2cd@yeah.net
86+18384252874
Yong He
study director · West China Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion